eISSN 2508-3589
pISSN 2508-1926

Table. 2.

Table. 2.

Comparisons of degree of change in BCVA during 1 month after aflibercept injection according to baseline characteristics

Characteristic Degree of Improvement in BCVA (logMAR) p-value*
Age (years) 0.639
≤ 61 0.15 ± 0.13
> 61 0.17 ± 0.12
Sex 0.981
Male 0.16 ± 0.12
Female 0.16 ± 0.14
Hypertension 0.869
Presence 0.16 ± 0.12
Absence 0.17 ± 0.13
Duration of diabetes mellitus (years) 0.059
≤ 10 0.13 ± 0.14
> 10 0.21 ± 0.09
Degree of diabetic retinopathy 0.482
Non-proliferative 0.19 ± 0.14
Proliferative 0.15 ± 0.12
Phakic status 0.408
Phakia 0.17 ± 0.13
Pseudophakia 0.12 ± 0.11
History of treatment for diabetic macular edema 0.177
Previous treatment (+) 0.18 ± 0.12
Previous treatment (-) 0.11 ± 0.11
BCVA (logMAR) 0.001
≤ 0.2 0.24 ± 0.12
> 0.2 0.08 ± 0.07
Central retinal thickness (μm) 0.037
≤ 500 0.11 ± 0.11
> 500 0.21 ± 0.12

Values are presented as mean ± standard deviation.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution.

*Statistical analysis was performed using Mann-Whitney U test.

J Retin 2021;6:34-40 https://doi.org/10.21561/jor.2021.6.1.34
© 2021 J Retin